Security key
30049G203
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 1,582,162
- Total 13F shares
- 60,640
- Share change
- -1,780
- Total reported value
- $161,234
- Price per share
- $2.68
- Number of holders
- 10
- Value change
- -$4,397
- Number of buys
- 4
- Number of sells
- 3
Report period
Q4 2022
Institutions
10
Top holders
10
EVOK full security history
Newer quarter: Q1 2023
Previous quarter: Q3 2022
Evoke Pharma Inc SEC filings
Evoke Pharma Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 30049G203
Recent filing periods:
Top shareholders of EVOK - Evoke Pharma, Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
29,851
|
$56,000 | — | 30 Sep 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
20,894
|
$39,000 | — | 30 Sep 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.5%
|
7,977
|
$15,000 | — | 30 Sep 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.14%
|
2,248
|
$4,000 | — | 30 Sep 2022 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
1,107
|
$2,000 | — | 30 Sep 2022 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
338
|
$1,000 | — | 30 Sep 2022 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
5
|
$9 | — | 30 Sep 2022 | |
| Ann D. Rhoads |
3/4/5
|
Director |
—
class O/S missing
|
61,750
|
— | — | 05 May 2021 |
Institutional Holders of Evoke Pharma, Inc. - Common Shares (EVOK) as of Q4 2022
As of 31 Dec 2022,
Evoke Pharma, Inc. - Common Shares (EVOK) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
60,640 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., UBS Group AG, Tower Research Capital LLC (TRC), Lindbrook Capital, LLC, PNC Financial Services Group, Inc., WELLS FARGO & COMPANY/MN, MORGAN STANLEY, and Federation des caisses Desjardins du Quebec.
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
7
Q4 2022 holders
10
Holder diff
3
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 Value $ | Q4 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.